William Edward Boden MD
Professor, Cardiovascular Medicine
Lecturer in Medicine
150 S Huntington Avenue | (857) 364-4201william.boden@va.gov
Sections
Cardiovascular Medicine
Biography
I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.
I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.
Other Positions
Education
Medicine-Internal, MD, State University of New York at Brockport
Biology, BS, Le Moyne College
Publications
Singh A, Brown DL, Jones PG, Fu Z, Reynolds HR, Boden WE, O'Brien SM, Mavromatis K, Poh KK, Ali Z, Stone GW, Bangalore S, Spertus JA, Maron DJ, Hochman JS. Residual Angina Following Complete Revascularization in the ISCHEMIA Trial: Frequency, Clinical Characteristics, Health Status, and Cardiovascular Outcomes. J Am Heart Assoc. 2026 May 19; 15(10):e047355. PMID: 42132177.
Published on 4/24/2026Kawczynski MJ, Barili F, Brophy JM, De Caterina R, Biondi Zoccai G, Anselmi A, Boden WE, Parolari A, Heuts S. Revascularisation strategies for non-acute myocardial ischaemic syndromes. Heart. 2026 Apr 24; 112(10):530-538. PMID: 40947142.
Published on 4/13/2026Grodzinsky A, Cho YJ, Jones PG, Shaw L, Merz CNB, Boden W, Stone G, Mark DB, Spertus JA, Maron DJ, Hochman JS, Reynolds HR. Sex Differences in Coronary Disease Health Status Outcomes: the ISCHEMIA Trial. Eur Heart J Qual Care Clin Outcomes. 2026 Apr 13. PMID: 41978343.
Published on 3/24/2026Weintraub WS, Boden WE. Does post-surgery cardiology evaluation improve clinical outcome in patients with a peri-operative myocardial infarction? Eur Heart J. 2026 Mar 24; 47(12):1484-1486. PMID: 41610885.
Published on 3/6/2026Park DW, Boden WE, De Caterina R, Gallinoro E, Ahn JM, Bairey Merz CN, Kaski JC, Kang DY, Kaul S, Marzilli M, Pepine CJ, Park SJ, Barbato E. Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques. Eur Heart J. 2026 Mar 06. PMID: 41790132.
Published on 2/23/2026Gorog DA, de Silva R, Boden WE. The year in cardiovascular medicine 2025: the top 10 papers in ischaemic heart disease. Eur Heart J. 2026 Feb 23. PMID: 41725250.
Published on 2/19/2026Chiu N, Bhatt DL, De Caterina R, Doenst T, Kirov H, Dayan V, Faxon DP, Kaul S, Perera D, Puskas JD, Steg PG, Boden WE. Invasive and medical management approaches to non-acute myocardial ischaemic syndromes. Nat Rev Cardiol. 2026 Feb 19. PMID: 41714707.
Published on 2/5/2026Boden WE. Exploring a New "Reef" in Dyslipidemic Risk Reduction. N Engl J Med. 2026 Feb 05; 394(6):597-599. PMID: 41885976.
Published on 12/30/2025Lopes MS, Boden WE. Early combination therapy for angina pectoris: How COMBINE offers new management insights to an old drug. Int J Cardiol. 2026 Mar 15; 447:134133. PMID: 41478451.
Published on 12/5/2025Kwong RY, Heydari B, Abbasi S, Mongeon FP, Marcotte F, Friedrich M, Shaw LJ, Xu Y, Anthopolos R, Bekeredjian R, Monti L, Selvanayagam J, Lesiak M, Picard MH, Berman DS, Bangalore S, Spertus JA, Stone GW, Boden WE, Min J, Mancini GBJ, Leipsic J, Budoff M, Hague C, Hochman JS, Maron DJ, Reynolds HR. Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial. JACC Cardiovasc Imaging. 2026 Mar; 19(3):326-341. PMID: 41351610.
Media Mentions
Published on 2/4/2026
Experimental cholesterol-lowering pill may offer new option for millions
Published on 6/25/2025
Therapeutic strategies to lower residual dyslipidemic CV risk beyond LDL-C and statins
Published on 2/19/2024
Published on 5/9/2023
Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups
Published on 1/25/2022
Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?
Published on 6/28/2021
'Profound' Benefit Found for Staying on Meds Long After Coronary Revascularization
Published on 5/27/2021
Contentious ISCHEMIA Deep Dive: Extent of Revascularization Key?
Published on 5/19/2021
Meta-analysis Muses Over ISCHEMIA Message Had Trial Lasted Longer
Published on 1/5/2021
Stable CAD With High-Risk Anatomy Warrants PCI or CABG, APPROACH Suggests
Published on 6/26/2020
Economic value of alirocumab good if LDL greater than 100 mg/dL
View full list of 12 media mentions.